'Bat-sh*t crazy': Biopharma leaders on regulatory chaos Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 10 February, 2026

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

presented by 7 Re­al-World Ways RWE Is Trans­form­ing Health­care

news 'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back Hengrui, Kailera push obesity pill ahead on promising mid-stage China data CSL’s CEO Paul McKenzie exits after rough few years

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group United States Vice President, Drug Metabolism & Pharmacokinetics (DMPK) C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

endpoints pharma The FDA ad crackdown has pharma's attention. But companies aren't 'radically changing course' — yet With scant data, RFK Jr. credits Trump tariffs for higher drug prices in Europe FDA rejects Regenxbio's Hunter syndrome gene therapy QuantX raises $85M Series B co-led by Lilly and Sanofi, aiming to replicate Kymera STAT6 success

in case you missed it 1. Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition 2. Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages 3. Takeda, Iambic sign AI drug discovery deal with up to $1.7B in milestones 4. A confluence of factors contributed to Sanofi's Phase 3 multiple sclerosis trial fail 5. Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial 6. Lilly returns to Innovent to partner on cancer and immune diseases 7. News Briefing Galux raises $29M Series B; CSL teams up with Memo 8. India's Lupin settles US patent dispute with Astellas Pharma for $90 million 9. Novo’s Obesity Pill TV Ad Includes Misleading Claims, FDA Says